Nanjing Pharmaceutical
Nanjing Pharmaceutical Co., Ltd., commonly referred to as Nanjing Pharma, is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in Nanjing, China. Established in 1995, the company has made significant strides in developing high-quality pharmaceutical products, focusing on both generic and innovative medications.
With a strong operational presence across various regions in China, Nanjing Pharma excels in producing a diverse range of core products, including injectables, tablets, and capsules. Their commitment to quality and adherence to international standards set them apart in a competitive market.
Recognised for their robust research and development capabilities, Nanjing Pharma has achieved notable milestones, positioning itself as a trusted name in the pharmaceutical sector. The company continues to expand its market reach, driven by a dedication to improving healthcare outcomes globally.
-18 vs industry average
Nanjing Pharmaceutical’s score of 20 is lower than 27% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Nanjing Pharmaceutical?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
Nanjing Pharmaceutical's reported carbon emissions
Nanjing Pharmaceutical, headquartered in CN and operating within the Pharmaceutical Preparation Manufacturing industry, reported a total of approximately 67.6 million kg CO2e for the year 2023. This figure encompasses Scope 1 and Scope 2 emissions. Specifically, Scope 1 emissions were approximately 5.0 million kg CO2e, and Scope 2 emissions totalled approximately 62.6 million kg CO2e.
In 2022, the company's total emissions were approximately 69.3 million kg CO2e, with Scope 1 at about 5.3 million kg CO2e and Scope 2 at approximately 64.0 million kg CO2e. For 2021, Nanjing Pharmaceutical reported total emissions of approximately 60.5 million kg CO2e, comprising around 4.5 million kg CO2e for Scope 1 and roughly 56.0 million kg CO2e for Scope 2.
The company's data for these years does not include Scope 3 emissions. Nanjing Pharmaceutical has not disclosed specific reduction targets or commitments at this time.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Nanjing Pharmaceutical’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Nanjing Pharmaceutical yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Nanjing Pharmaceutical
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project